379 related articles for article (PubMed ID: 28753317)
1. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
[TBL] [Abstract][Full Text] [Related]
2. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
3. Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy.
Wang W; Chen K; Su Y; Zhang J; Li M; Zhou J
Biomacromolecules; 2018 Feb; 19(2):438-448. PubMed ID: 29334216
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
5. Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle.
Yang Y; Meng Y; Ye J; Xia X; Wang H; Li L; Dong W; Jin D; Liu Y
J Control Release; 2018 Oct; 287():103-120. PubMed ID: 30144476
[TBL] [Abstract][Full Text] [Related]
6. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
[TBL] [Abstract][Full Text] [Related]
7. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
[TBL] [Abstract][Full Text] [Related]
8. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
9. Coloaded Nanoparticles of Paclitaxel and Piperlongumine for Enhancing Synergistic Antitumor Activities and Reducing Toxicity.
Liu Q; Zhao D; Zhu X; Chen H; Yang Y; Xu J; Zhang Q; Fan A; Li N; Guo C; Kong Y; Lu Y; Chen X
J Pharm Sci; 2017 Oct; 106(10):3066-3075. PubMed ID: 28552690
[TBL] [Abstract][Full Text] [Related]
10. Green design "bioinspired disassembly-reassembly strategy" applied for improved tumor-targeted anticancer drug delivery.
Wang R; Gu X; Zhou J; Shen L; Yin L; Hua P; Ding Y
J Control Release; 2016 Aug; 235():134-146. PubMed ID: 27238442
[TBL] [Abstract][Full Text] [Related]
11. Dual-functional bio-derived nanoparticulates for apoptotic antitumor therapy.
Ding Y; Wang Y; Opoku-Damoah Y; Wang C; Shen L; Yin L; Zhou J
Biomaterials; 2015 Dec; 72():90-103. PubMed ID: 26344366
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel.
McConathy WJ; Nair MP; Paranjape S; Mooberry L; Lacko AG
Anticancer Drugs; 2008 Feb; 19(2):183-8. PubMed ID: 18176115
[TBL] [Abstract][Full Text] [Related]
13. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
15. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
[TBL] [Abstract][Full Text] [Related]
17. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
18. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
19. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier.
Mooberry LK; Nair M; Paranjape S; McConathy WJ; Lacko AG
J Drug Target; 2010 Jan; 18(1):53-8. PubMed ID: 19637935
[TBL] [Abstract][Full Text] [Related]
20. A reconstituted thermosensitive hydrogel system based on paclitaxel-loaded amphiphilic copolymer nanoparticles and antitumor efficacy.
Liang Y; Dong C; Zhang J; Deng L; Dong A
Drug Dev Ind Pharm; 2017 Jun; 43(6):972-979. PubMed ID: 28121206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
